Scientists renew the search for measles drugs amid low vaccination rates

Researchers are renewing efforts to develop an FDA-approved drug for measles after outbreaks surged in the U.S. due to vaccine hesitancy. The virus, previously controlled by vaccination, has resurged since 2025, marking the worst measles cases in nearly 35 years. Currently, doctors can only manage symptoms like fever and rash, with no direct antiviral treatment available. A ‘crowded’ race to develop therapeutics has emerged, driven by the failure of ring vaccination—a strategy where contacts of infected individuals are vaccinated—in communities with low immunization rates. One leading candidate, GHP-88310, an oral antiviral developed at Georgia State University’s Center for Translational Antiviral Research, has shown promise in treating measles and related respiratory infections. Carolin Lieber, a senior postdoctoral fellow, called it the ‘most promising inhibitor’ of the virus family in years. The drug could provide a critical tool amid growing vaccine resistance, particularly in areas where outbreaks have occurred. While GHP-88310 has demonstrated effectiveness in lab and animal studies, its real-world impact remains uncertain. Researchers emphasize that widespread adoption would depend on further clinical trials and regulatory approval. Experts warn that even with a drug, vaccination remains the most effective long-term solution. The resurgence of measles highlights the consequences of declining immunization rates, with outbreaks disproportionately affecting unvaccinated communities. Public health officials stress the need for both vaccine education and alternative treatments to curb future spread.